Uniting CNS Biopharma to Revolutionize the Next Wave of Neurodegenerative Therapeutics
Welcome to the 11th Alzheimer’s & Parkinson’s Drug Development Summit
With a surge in preclinical investment, fresh news of clinical pipeline progressions, and a new era of therapies pending FDA approvals from Biogen, Eisai, and Denali Therapeutics, 2022 has put neurodegenerative drug development back on the map.
Building on the field’s momentum, we are delighted to bring back the 11th Alzheimer’s & Parkinson’s Drug Development Summit, dedicated to overcoming the translational challenges of targeting neurodegenerative mechanisms. This summit will unite neurodegenerative biopharma experts from discovery, preclinical, translational, and clinical backgrounds to showcase the latest breakthroughs in Alzheimer’s, Parkinson’s, and related neurological disorders in 2022 and 2023.
Expert Speakers Included:
Global Biomarker Diagnostic & Neuroscience Lead
Associate Director, Biomarkers
Denali Therapeutics Inc.
Vice President - Neuroscience Data Science & Digital Health
Johnson & Johnson Services, Inc
Executive Medical Director - Neurodegeneration Development Unit, Head of Movement Disorders
Associate Vice President, Digital Health Research & Development
Eli Lilly & Co.
Hear from the previous attendees:
“Informative talks, stimulating panel discussions, dedicated workshops, and challenging
questions from an interactive and engaged audience”
Director, BioInnovation & Global Head of External Innovation, Research & Development, Servier